These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 29391042)

  • 21. The Global Programme to Eliminate Lymphatic Filariasis: health impact during its first 8 years (2000-2007).
    Hooper PJ; Bradley MH; Biswas G; Ottesen EA
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S17-21. PubMed ID: 19843394
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lymphatic filariasis: patients and the global elimination programme.
    Mackenzie CD; Lazarus WM; Mwakitalu ME; Mwingira U; Malecela MN
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S41-51. PubMed ID: 19843397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Economic performance and cost-effectiveness of using a DEC-salt social enterprise for eliminating the major neglected tropical disease, lymphatic filariasis.
    Sharma S; Smith ME; Reimer J; O'Brien DB; Brissau JM; Donahue MC; Carter CE; Michael E
    PLoS Negl Trop Dis; 2019 Jul; 13(7):e0007094. PubMed ID: 31260444
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translating Research into Reality: Elimination of Lymphatic Filariasis from Haiti.
    Lammie PJ; Eberhard ML; Addiss DG; Won KY; Beau de Rochars M; Direny AN; Milord MD; Lafontant JG; Streit TG
    Am J Trop Med Hyg; 2017 Oct; 97(4_Suppl):71-75. PubMed ID: 29064364
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis.
    Krentel A; Gyapong M; McFarland DA; Ogundahunsi O; Titaley CR; Addiss DG
    Int Health; 2020 Dec; 13(Supplement_1):S55-S59. PubMed ID: 33349882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recent advances in the chemotherapy of lymphatic filariasis.
    Navaratnam V
    Southeast Asian J Trop Med Public Health; 1993; 24 Suppl 2():51-4. PubMed ID: 7973948
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lessons from lymphatic filariasis elimination and the challenges of post-elimination surveillance in China.
    Fang Y; Zhang Y
    Infect Dis Poverty; 2019 Aug; 8(1):66. PubMed ID: 31387644
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Global programme to eliminate lymphatic filariasis.
    Wkly Epidemiol Rec; 2010 Sep; 85(38):365-72. PubMed ID: 20853547
    [No Abstract]   [Full Text] [Related]  

  • 29. Determinants of parasite drug resistance in human lymphatic filariasis.
    Cobo F
    Rev Esp Quimioter; 2016 Dec; 29(6):288-295. PubMed ID: 27858056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salt fortified with diethylcarbamazine (DEC) as an effective intervention for lymphatic filariasis, with lessons learned from salt iodization programmes.
    Houston R
    Parasitology; 2000; 121 Suppl():S161-73. PubMed ID: 11386687
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs.
    Mathew CG; Bettis AA; Chu BK; English M; Ottesen EA; Bradley MH; Turner HC
    Clin Infect Dis; 2020 Jun; 70(12):2561-2567. PubMed ID: 31343064
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Global programme to eliminate lymphatic filariasis.
    Wkly Epidemiol Rec; 2007 Oct; 82(42):361-80. PubMed ID: 17948605
    [No Abstract]   [Full Text] [Related]  

  • 33. Global programme to eliminate lymphatic filariasis: progress report, 2011.
    Wkly Epidemiol Rec; 2012 Sep; 87(37):346-56. PubMed ID: 22977953
    [No Abstract]   [Full Text] [Related]  

  • 34. Pacific collaboration to eliminate lymphatic filariasis.
    Ichimori K; Crump A
    Trends Parasitol; 2005 Oct; 21(10):441-4. PubMed ID: 16099721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress and impact of 20 years of a lymphatic filariasis elimination programme in South-East Asia.
    Kapa DR; Mohamed AJ
    Int Health; 2020 Dec; 13(Suppl 1):S17-S21. PubMed ID: 33349881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GlaxoSmithKline and Merck: private-sector collaboration for the elimination of lymphatic filariasis.
    Gustavsen KM; Bradley MH; Wright AL
    Ann Trop Med Parasitol; 2009 Oct; 103 Suppl 1():S11-5. PubMed ID: 19843393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mass drug treatment for lymphatic filariasis and onchocerciasis.
    Molyneux DH; Bradley M; Hoerauf A; Kyelem D; Taylor MJ
    Trends Parasitol; 2003 Nov; 19(11):516-22. PubMed ID: 14580963
    [No Abstract]   [Full Text] [Related]  

  • 38. Lymphatic filariasis and onchocerciasis prevention, treatment, and control costs across diverse settings: a systematic review.
    Keating J; Yukich JO; Mollenkopf S; Tediosi F
    Acta Trop; 2014 Jul; 135():86-95. PubMed ID: 24699086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Call to consolidate achievements for onchocerciasis and lymphatic filariasis control.
    Hoerauf A; Walter RD; Remme H; Lazdins J; Fleischer B
    Trends Parasitol; 2001 Dec; 17(12):566-7. PubMed ID: 11756020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Eliminating Lymphatic Filariasis: Is it Worth it?
    Niessen LW; Taylor ML
    Clin Infect Dis; 2020 Jun; 70(12):2568-2569. PubMed ID: 31343066
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.